Gregory Burshtein - Jul 16, 2025 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role: Chief of R&D
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-fact
Stock symbol: ENTX
Transactions as of: Jul 16, 2025
Transactions value $: $0
Form type: 4
Date filed: 7/18/2025, 04:35 PM
Previous filing: Jun 7, 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Burshtein Gregory	Chief of R&D	KIRYAT HADASSAH, MINRAV BUILDING,, FIFTH FLOOR, JERUSALEM, ISRAEL	/s/ Dana Yaacov-Garbeli, Attorney-in-fact	2025-07-18	0002026002

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	$0	+26.3K	+35.03%	$0.00	101K	Jul 16, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENTX	Stock Option (right to buy)	Award	$0	+200K		$0.00	200K	Jul 16, 2025	Ordinary Shares, par value NIS 0.0000769 per share	200K	$2.28	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.
F2	This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

Content

Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.

This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.